"I believe there is now more than enough evidence that CF33 is...

"I believe there is now more than enough evidence that CF33 is an extremely valuable asset."

Yep, I believe the same now too and while we've only received results so far for Vaxinia, let's not forget onCARlytics is not far behind.

For those that aren't aware, the onCARlytics trial is aiming to enrol 52 patients and has an estimated Primary Completion date of September 2024 compared to the Vaxinia trial of 100 patients with an estimated Primary Completion date of December 2024. The smaller numbers for the onCARlytics trial almost certainly stems from starting at a higher dose thanks to the early Vaxinia trial cohorts lifting the starting point removing the need to progress through lower doses, as well as not having a trial arm in combination with Pembrolizumab. So, all up, we'll probably end up with similar numbers at OBD in both studies.

The FPI (First Patient In) for the onCARlytics trial was announced on 26/10/2023, which is 84 days (4 x 21 days) today, and while I'm not expecting an update anytime soon, the researchers will be starting to get an idea of how onCARlytics by itself compares to Vaxinia. I haven't seen anything to show how the onCARlytics cohorts are structed but hopefully they're almost on par with Vaxinia and also, we're probably close to hearing about FPI for the onCARlytics/Blinatumomab arm.